SensiLase PAD-IQ can go wherever you treat patients; a ruggedized, customized roller bag keeps the product safe and has ample room for supplies. SensiLase PAD-IQ features access to the internet via Bluetooth, WiFi or Ethernet while Studycast permits you to log-in from anywhere to upload data and images for expert consult and secure data storage.
Väsamed’s SensiLase PAD-IQ System featuring Studycast Data Management offers health professionals numerous support tools for both PAD and CLI to enable noninvasive vascular diagnostics, data communication and management. Read more about tissue perfusion, reactive hyperemia, volume plethysmography and wound imaging here.
Patients over age 50 and who also have a history of diabetes or history of smoking are at risk of PAD. Even patients under age 50 but who have diabetes and risk factors such as obesity, high blood pressure, a history of non-healing ulcers, erectile dysfunction (ED) or kidney disease (CKD/ESRD) are at risk. Consult your doctor if you exhibit these risk-factors.
In this article about the Podiatrist’s role in preventing diabetic foot amputation, Dr. Ross Talarico (Chief and Residency Director of the Podiatric Surgery Service at the San Francisco Veterans Affairs Medical Center) offers a protocol rooted in objective and evidence-based patient assessment. Within the protocol, the author focuses on the importance of skin perfusion pressure assessments of at least two angiosomes of the foot. Additionally, podiatry and vascular cooperation within a multidisciplinary team are presented as core to a successful amputation prevention program. SensiLase PAD-IQ System performs a combination of peripheral arterial diagnostic tests to more accurately detect the presence and severity of disease. It combines micro and macrovascular assessments as well as visual documentation support tools that are useful when a wound is present. Note that PAD-IQ supports several of the options recommended by the Vascular Foundation and PAD Coalition for diagnosing PAD.
• Medical History and Physical Exam –SensiLase PAD-IQ (supports electronic documentation of all PAD risk factors)
• Ankle-Brachial Index (ABI) – SensiLase PAD-IQ
• Treadmill Exercise Test – SensiLase PAD-IQ (supports electronic documentation of pre and post exercise results)
• Reactive Hyperemia Test – SensiLase PAD-IQ
• Segmental Pressure Measurements
• PVR Waveform Analysis – SensiLase PAD-IQ
• Duplex Arterial Imaging or Ultrasound Imaging
• Photoplethysmography (PPG)
Shown here are Väsamed Inc CEO, Paulita LaPlante and Solvit Medical CEO, Ki Sung Kim, in Solvit’s exhibit booth for SensiLase PAD-IQ at the 2013 International Conference on Diabetes and Metabolism & 5th AASD Scientific Meeting, 6-10 November 2013 at the Grand Hilton hotel. The prevalence of diabetes in Korea has increased six- to seven-fold from 1.5% to 9.9% in the past 40 years. The International Diabetes Federation has estimated that the prevalence of diabetes will rise to 11.4% in 2030. With diabetes comes increased risk of peripheral arterial disease (PAD) and the need for timely, accurate PAD detection and monitoring.
"Väsamed's booth at Desert Foot 2013, 20-22 November at The Sheraton Phoenix Downtown in Phoenix, AZ. Conference Chairman Robert G. Frykberg, DPM, MPH, has again invited leaders in diabetic foot management. All exhibitors owe thanks to this meeting's premier sponsor-Smith & Nephew-for their generous contribution to this premier event for VA and IHS healthcare providers!" -John Campbell